<DOC>
	<DOCNO>NCT02229266</DOCNO>
	<brief_summary>The trial investigate efficacy adoptive immunotherapy haploidentical natural killer cell compare standard chemotherapy ( first complete remission ) patient high-risk acute myeloid leukemia old 65 year age eligible allogeneic transplantation</brief_summary>
	<brief_title>Randomised Controlled Phase-2 Trial Determine Efficacy Adoptive Immunotherapy With NK Cells High-risk AML</brief_title>
	<detailed_description>Randomised control phase-2 trial determine efficacy adoptive immunotherapy haploidentical natural killer cell high-risk acute myeloid leukemia</detailed_description>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Leukemia , Myeloid</mesh_term>
	<mesh_term>Leukemia , Myeloid , Acute</mesh_term>
	<mesh_term>Cytarabine</mesh_term>
	<criteria>Newly diagnose AML acute promyelocytic leukemia ( APL ) accord WHO criteria In AML define cytogenetic aberration proportion blast may &lt; 20 % Age ≥60 year Clinical performance correspond ECOG score 02 Highrisk karyotype &lt; 5 % myeloblast bone marrow ≥21 day begin recent chemotherapy maximal two precede chemotherapy cycle Potentially available haploidentical family donor ( child/ sibling ) , willing fit NK cell donation AML favorable intermediate risk cytogenetic feature Persistent aplasia follow precede chemotherapy Relapsed refractory AML Known preexist autoimmune disease Any severe concomitant condition make undesirable patient participate study Any condition could jeorpadize compliance protocol Participation another clinical trial within 4 week study entry</criteria>
	<gender>All</gender>
	<minimum_age>60 Years</minimum_age>
	<maximum_age>99 Years</maximum_age>
	<verification_date>January 2016</verification_date>
	<keyword>AML</keyword>
	<keyword>high-risk AML</keyword>
	<keyword>acute myeloid leukemia</keyword>
	<keyword>NK cell</keyword>
	<keyword>haploidentical natural killer cell</keyword>
	<keyword>immunotherapy</keyword>
</DOC>